Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7

J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell, David R. Jones, James Eckstein, Kenneth Ruterbories, Mitchell A. Hamman, Stephen D. Hall, Steven A. Wrighton

Research output: Contribution to journalArticle

329 Citations (Scopus)

Abstract

The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, Km or S50 values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1′-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 ≈ CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.

Original languageEnglish
Pages (from-to)883-891
Number of pages9
JournalDrug Metabolism and Disposition
Volume30
Issue number8
DOIs
StatePublished - 2002

Fingerprint

Cytochrome P-450 CYP3A
Metabolites
Substrates
Biotransformation
Triazolam
Cytochromes b5
Clarithromycin
Diltiazem

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Andrew Williams, J., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., ... Wrighton, S. A. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition, 30(8), 883-891. https://doi.org/10.1124/dmd.30.8.883

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. / Andrew Williams, J.; Ring, Barbara J.; Cantrell, Varon E.; Jones, David R.; Eckstein, James; Ruterbories, Kenneth; Hamman, Mitchell A.; Hall, Stephen D.; Wrighton, Steven A.

In: Drug Metabolism and Disposition, Vol. 30, No. 8, 2002, p. 883-891.

Research output: Contribution to journalArticle

Andrew Williams, J, Ring, BJ, Cantrell, VE, Jones, DR, Eckstein, J, Ruterbories, K, Hamman, MA, Hall, SD & Wrighton, SA 2002, 'Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7', Drug Metabolism and Disposition, vol. 30, no. 8, pp. 883-891. https://doi.org/10.1124/dmd.30.8.883
Andrew Williams J, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition. 2002;30(8):883-891. https://doi.org/10.1124/dmd.30.8.883
Andrew Williams, J. ; Ring, Barbara J. ; Cantrell, Varon E. ; Jones, David R. ; Eckstein, James ; Ruterbories, Kenneth ; Hamman, Mitchell A. ; Hall, Stephen D. ; Wrighton, Steven A. / Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. In: Drug Metabolism and Disposition. 2002 ; Vol. 30, No. 8. pp. 883-891.
@article{866f4c757fdb4001bb4db4ebb266990b,
title = "Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7",
abstract = "The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50{\%} of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, Km or S50 values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1′-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 ≈ CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.",
author = "{Andrew Williams}, J. and Ring, {Barbara J.} and Cantrell, {Varon E.} and Jones, {David R.} and James Eckstein and Kenneth Ruterbories and Hamman, {Mitchell A.} and Hall, {Stephen D.} and Wrighton, {Steven A.}",
year = "2002",
doi = "10.1124/dmd.30.8.883",
language = "English",
volume = "30",
pages = "883--891",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "8",

}

TY - JOUR

T1 - Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7

AU - Andrew Williams, J.

AU - Ring, Barbara J.

AU - Cantrell, Varon E.

AU - Jones, David R.

AU - Eckstein, James

AU - Ruterbories, Kenneth

AU - Hamman, Mitchell A.

AU - Hall, Stephen D.

AU - Wrighton, Steven A.

PY - 2002

Y1 - 2002

N2 - The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, Km or S50 values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1′-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 ≈ CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.

AB - The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, Km or S50 values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1′-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 ≈ CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.

UR - http://www.scopus.com/inward/record.url?scp=0036320872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036320872&partnerID=8YFLogxK

U2 - 10.1124/dmd.30.8.883

DO - 10.1124/dmd.30.8.883

M3 - Article

C2 - 12124305

AN - SCOPUS:0036320872

VL - 30

SP - 883

EP - 891

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 8

ER -